Clinical trials: Resectable Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by gemcitabine (300 mg/m2/week) combined with…
- Trial name
- GEMCAD1003 (NCT01389440)
- Testing
- Gemcitabine and Erlotinib
- Where
- 10 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Resectable Pancreatic Cancer
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions.
- Trial name
- NeoPancOne (NCT04472910)
- Testing
- Modified Folforinox (mFFX)
- Where
- 8 sites in Canada
- Volunteers
- 84 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021[7]-2030[6]), including a multidisciplinary training program…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Non-resectable, Chemotherapy Effect
- Trial name
- PREOPANC-4 (NCT05524090)
- Testing
- Implementation - International best-practice care
- Where
- Netherlands
- Volunteers
- 223 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Neoplasm
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
This phase II trial studies how well combination chemotherapy works in treating patients with pancreatic cancer before undergoing surgery.
- Conditions
- Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Neoplasm, Resectable Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT02345460
- Testing
- Irinotecan Hydrochloride, Oxaliplatin, Leucovorin Calcium
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pancreatic Adenocarcinoma Resectable
A Pilot Study of IRE for Resectable Pancreatic Cancer
The operation to remove certain pancreatic cancers (Whipple procedure), even in 2017, remains one of the most complicated surgeries done in the abdomen.
- Trial name
- NCT03337997
- Testing
- Irreversible Electroporation
- Where
- Canada
- Sponsor
- University of Saskatchewan
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Adenocarcinoma Resectable
Adjuvant Pancreatic Therapy Guided by MRD
Pancreatic adenocarcinoma (PAAD) is a leading cause of cancer-related deaths worldwide. Although surgical resection can be curative, the 5-year overall survival (OS) rate after resection alone is approximately 20%.
- Trial name
- ADAPT-MRD (NCT06966440)
- Testing
- circulating tumor DNA (ctDNA)-based MRD, adjuvant chemotherapy regimens
- Where
- China
- Volunteers
- 856 people
- Sponsor
- Ruijin Hospital